Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Figures corrected NBB
Corrected annual account filed for 2025.
Financials
Financial year 2025
Sagitta Biotech from Liège, company number BE0724569610, closed financial year 2025 with a result of € -354,671 after tax. For that financial year Sagitta Biotech recorded a gross margin of € -138,661 and equity of € 353,411. Compared with financial year 2024, the result moved from € -379,488 to € -354,671. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 15, 2026.
€ 353,411
▲ € 426,327 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -354,671
▲ 7 % less loss than in 2024
Profit after tax over the fiscal year.
€ 148,081
▲ 256% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.1 million.
People and assets in 2025
€ 174,924
▲ 6% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,514
▲ 4% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2,503
▼ 47% vs 2024
Loans from banks and other lenders, long and short.
€ 400,236
▲ 256% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 16,537
▼ 48% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -20,179 | € -305,249 | € -184,289 | € -138,661 | ▲ € 45,629 |
| Profit after taxes | € -21,229 | € -329,760 | € -379,488 | € -354,671 | ▲ € 24,817 |
| Equity | € -13,667 | € 306,573 | € -72,915 | € 353,411 | ▲ € 426,327 |
| Total debts | € 29,645 | € 508,987 | € 539,606 | € 628,260 | ▲ 16% |
| Cash | € 73 | € 649,450 | € 41,642 | € 148,081 | ▲ 256% |
| Retained profit | € -33,667 | € -363,427 | € -742,915 | € -1,097,587 | ▼ € 354,671 |
| Bank debt | € 0 | € 688 | € 4,703 | € 2,503 | ▼ 47% |
| Balance sheet total | € 15,978 | € 815,560 | € 466,690 | € 981,671 | ▲ 110% |
Key figures of Sagitta Biotech, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Sagitta Biotech?
What happened at Sagitta Biotech in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- NEMESIS CONSULTING SA SA stepped down as director. NBB
- NOSHAQ PARTNERS SRL SRL stepped down as director. NBB
- Didier Allaer stepped down as director. NBB
- Corrected annual accounts filed for financial year 2025. Source: NBB ↗
- NOSHAQ PARTNERS SRL SRL became a director. NBB
- Didier Allaer became a director. NBB
- New establishment in Liège. KBO
- NEMESIS CONSULTING SA SA became a director. NBB
In short
From € 21,229 loss in 2022 to € 354,671 loss in 2025.
A new publication or filing at Sagitta Biotech? We notify you, reason included.
Follow Sagitta BiotechDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of NOSHAQ SPIN-OFFS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Sagitta BiotechThe shares are held by NOSHAQ SPIN-OFFS (34.6%).
Directors
According to the 2025 annual accounts
Director · represented by Damien Benjamin
since 2019 · until 2029
Director · represented by Schynts Frédéric
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +169 more
since 2023 · until 2029
Shareholders
34.6%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Avenue Hippocrate 5 box GIGA
4000 Liège
Avenue Pré-Aily 10
4031 Liège
Active since 4 April 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →XeroThera Europe
€ 196,870 gross margin · 2025
QUIDDITAS
€ 175,986 gross margin · 2025
ARTIALIS same network
€ 320,267 gross margin · 2024
Temple OrthoBiologics
€ -225,322 gross margin · 2025
BRENUS PHARMA BELGIUM
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0724.569.610
- VAT number
- BE 0724.569.610
- Registered office
- Avenue Hippocrate 5 bus GIGA, 4000 Liège
- Names & denominations
- Sagitta Biotech
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 4 April 2019
- Peppol
- Active · Active since 24 Mar 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied